Scoop.it

Qure.ai’s qXR solution can detect findings that are indicative of COVID-19 and also quantify the volume of the infection.

Source: www.mobihealthnews.com

L'Ile-de-France va expérimenter l'application de contact tracing StopC19 développée par Orange, Capgemini, Dassault Systèmes, Sopra Steria et SIA Partners. Cet outil repose sur l'utilisation du Bluetooth pour retracer les chaînes de transmission du virus, un fonctionnement semblable à l'application gouvernementale StopCovid en cours de développement. A mesure que les dispositifs de pistage se multiplient, se pose néanmoins la question de leur future articulation.

Source: www.usine-digitale.fr

For champions of AI in healthcare, the COVID-19 crisis affords an unignorable opportunity to trumpet the technology’s current contributions while directing attention to its potential for helping fight public-health crises to come.

As vice chair of the Alliance for Artificial Intelligence in Healthcare, Brandon Allgood, PhD, is up for the assignment.

In a contributed piece published by The Hill, Allgood recaps some themes that emerged as AI entered the healthcare ecosystem—streamlining clinical workflows, speeding clinical diagnostics, enabling drug discovery—before taking a look at what some specific AI companies are doing to help battle COVID.

Among the businesses he introduces is New York-based Envisagenics, which has developed an AI platform that analyzes 1,000 polymerise chain reaction (PCR) testing samples in two hours. The current analysis takes up to two days.

“Time saves lives,” Allgood writes, “and the company hopes to release the platform for commercial use in the coming weeks.”

Allgood also summarizes the AI-incorporating products and services of Montreal-based Hexoskin (remote monitoring of biometrics data), San Francisco-based Auransa (personalized drug recommendations), UK-based Medopad (biomarker-associated risk factor identification) and others.

Source: www.aiin.healthcare

Rizwan Malik had always had an interest in AI. As the lead radiologist at the Royal Bolton Hospital, run by the UK’s National Health Service (NHS), he saw its potential to make his job easier. In his hospital, patients often had to wait six hours or more for a specialist to look at their x-rays. If an emergency room doctor could get an initial reading from an AI-based tool, it could dramatically shrink that wait time. A specialist could follow up the AI system’s reading with a more thorough diagnosis later.

So in September of last year, Malik took it upon himself to design a conservative clinical trial that would help showcase the technology’s potential. He identified a promising AI-based chest x-ray system called qXR from the Mumbai-based company Qure.ai. He then proposed to test the system over six months. For all chest x-rays handled by his trainees, it would offer a second opinion. If those opinions consistently matched his own, he would then phase the system in permanently to double-check his trainees’ work for him. After four months of reviews from multiple hospital and NHS committees and forums, the proposal was finally approved.

But before the trial could kick off, covid-19 hit the UK. What began as a pet interest suddenly looked like a blessing. Early research had shown that in radiology images, the most severe covid cases displayed distinct lung abnormalities associated with viral pneumonia. With shortages and delays in PCR tests, chest x-rays had become one of the fastest and most affordable ways for doctors to triage patients.

Source: www.technologyreview.com